

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Application of:

KATSUO KUMAGAI, ET AL.

Serial No. **10/629,117**

Filed: **July 28, 2003**

For: **THERAPEUTIC AGENT FOR MASTITIS OF
LIVESTOCK AND METHOD FOR
TREATING MASTITIS USING THE
SAME AGENT**

)
)
)
)
) Art Unit: **1623**
)
) Examiner: **G. Krishnan**
)
)
)
)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98A copy of each cited item is enclosed unless stated otherwise hereinbelow.

Pursuant to 37 C.F.R. §1.98(d), inasmuch as this application relies on prior application Serial No. 09/995,040 filed November 26, 2001 for an earlier filing date under 35 U.S.C. § 120, no copy of any patent, publication or other information previously cited by or submitted to the Office in such prior application is being provided herewith.

As this Information Disclosure Statement is being filed after the issuance of an office action on the merits, pursuant to 37 C.F.R. §1.97(c)(2), please charge the fee of \$180, as set forth in §1.17(p), to Deposit Account Number 11-0855.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on August 23, 2004.


Elena S. Polovnikova, Ph.D. - Reg. No. 52,130

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Elena S. Polovnikova', with a stylized flourish at the end.

Elena S. Polovnikova, Ph.D.
Patent Agent
Reg. No. 52,130

KILPATRICK STOCKTON LLP
1100 Peachtree Street, Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
Docket: 44471/288235

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/629,117
		Filing Date	July 28, 2003
		First Named Inventor	KATSUO KUMAGAI
		Group Art Unit	1623
		Examiner Name	G. Krishnan
Sheet 2	of 2	Attorney Docket Number	44471/288235

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	5	Fujisawa, Yumiko, <i>et al.</i> , "Glycyrrhizin Inhibits the Lytic Pathway of Complement – Possible Mechanism of Its Anti-Inflammatory Effect on Liver Cells in Viral Hepatitis," <i>Microbiol. Immunol.</i> , Vol. 44, No. 9, pp. 799-804 (2000)	
	6	Fukai, Toshio, <i>et al.</i> , "Cytotoxic Activity of Low Molecular Weight Polyphenols against Human Oral Tumor Cell Lines," <i>Anticancer Research</i> , Vol. 20, pp. 2525-2536 (2000)	
	7	Jeong, H., <i>et al.</i> , "Induction of Inducible Nitric Oxide Synthase Expression by 18 β -glycyrrhetic Acid in Macrophages, <i>FEBS Letters</i> , Vol. 513., pp.208-212 (2002)	
	8	Kai, Kenzo, <i>et al.</i> , "Anti-inflammatory effects of Intramammary Infusions of Glycyrrhizin in Lactating Cows with Mastitis Caused by Coagulase-negative Staphylococci, <i>AJVR</i> , Vol. 64, No. 10, pp. 1213-1220 (2003)	
	9	Mishima, Mathiro <i>et al.</i> , "Studies on glycyrrhetinate and its derivatives as nasal absorption promoter of insulin," <i>Drug Delivery System</i> , p. 88.	
	10	Okada, Kenzo, <i>et al.</i> , "Identification of Antimicrobial and Antioxidant Constituents from Licorice of Russian and Xhijiang Origin, <i>Chem. Pharm. Bull.</i> , Vol. 37, No. 9, pp. 2528-2530 (1989)	
	11	Sakagami, H., <i>et al.</i> , "Induction of Apoptosis by Flavones, Flavonols (3-Hydroxyflavones) and Isoprenoid-Substituted Flavonoids in Human Oral Tumor Cell Lines", <i>Anticancer Research</i> , Vol. 20, pp. 271-278 (2000)	
	12	Suzuki, H., <i>et al.</i> , "Effects of Glycyrrhizin on Biochemical Tests in Patients with Chronic Hepatitis," <i>Asian Med. J.</i> , Vol. 26, No. 7, pp. 423-438.	
	13	Utsunomiya, Tokuichiro <i>et al.</i> , "Glycyrrhizin (20 β -carboxy-11-oxo-30-norolean-12-en-3 β -yl-2-O- β -D-glucopyranuronosyl- α -D-glucopyranosiduronic acid) improves the resistance of thermally injured mice to opportunistic infection of herpes simplex virus type 1," <i>Immunology Letters</i> , Vol. 44, pp. 59-66 (1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.